Symbiomix Therapeutics Report issue

Contributed to NME For profit Phase 3
Founded: Newark TX United States (2012)
Status: Acquired by Lupin (2017)

Organization Overview

First Clinical Trial
2014
NCT02147899
First Marketed Drug
2017
secnidazole (solosec)
First NDA Approval
2017
secnidazole (solosec)
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

secnidazole (solosec) (2017 NDA)

Drugs in Phase 3 Trials (1)

secnidazole (solosec) (3 trials)

Indications

Approved Indications


 

Giardiasis

Vaginosis, Bacterial

Experimental Indications (Clinical Trials, Phases 1-4)


 

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1